# Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol

Study · id `cardio:ct-nct07180472` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07180472](<https://clinicaltrials.gov/study/NCT07180472>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07180472

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 632 participants.

## Technical summary

Registry record NCT07180472. Randomized; no masking; primary purpose treatment. Start 2025-09-20 (anticipated); primary completion 2027-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 632 participants (planned count; ClinicalTrials.gov record NCT07180472, source copy `cardio:ctgov-nct07180472-2025-09-23`, retrieved 2026-11-18)
- Planned start: 2025-09-20 (anticipated) (ClinicalTrials.gov record NCT07180472, source copy `cardio:ctgov-nct07180472-2025-09-23`, retrieved 2026-11-18)
- Primary completion: 2027-09-01 (anticipated) (ClinicalTrials.gov record NCT07180472, source copy `cardio:ctgov-nct07180472-2025-09-23`, retrieved 2026-11-18)
- Completion: 2027-12-01 (anticipated) (ClinicalTrials.gov record NCT07180472, source copy `cardio:ctgov-nct07180472-2025-09-23`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07180472-2025-09-23`, retrieved 2026-11-18)

## The registry's words

- Brief title: Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol
- Condition: Cerebral Small Vessel Disease
- Intervention (Drug): Cilostazol
- Intervention (Drug): Aspirin
- Intervention (Drug): Clopidogrel
- Lead sponsor: First Affiliated Hospital of Chengdu Medical College
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cerebral small vessel disease (`cardio:cerebral-small-vessel-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital of Chengdu Medical College (`cardio:org-first-affiliated-hospital-of-chengdu-medical-college`)

## Provenance

Content hash: 09fd1a77fcf65d8cb9e8155033c575705079a99bb051baf6e6d205c2027684a9
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
